© 2024 Corcept Therapeutics, Incorporated
Difficult-to-Control Diabetes: Is Cortisol at Play?
• 2023 • Roundtable Discussion
Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
Alkhouri et al. • 2023 • AASLD 2023 Congress
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli et al. • 2023 • Italian Society of Endocrinology National Congress 2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli et al. • 2023 • ENDO 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • ENDO 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli et al. • 2023 • European Congress of Endocrinology
An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome
Badiu et al. • 2023 • European Congress of Endocrinology